<code id='3204B58D4A'></code><style id='3204B58D4A'></style>
    • <acronym id='3204B58D4A'></acronym>
      <center id='3204B58D4A'><center id='3204B58D4A'><tfoot id='3204B58D4A'></tfoot></center><abbr id='3204B58D4A'><dir id='3204B58D4A'><tfoot id='3204B58D4A'></tfoot><noframes id='3204B58D4A'>

    • <optgroup id='3204B58D4A'><strike id='3204B58D4A'><sup id='3204B58D4A'></sup></strike><code id='3204B58D4A'></code></optgroup>
        1. <b id='3204B58D4A'><label id='3204B58D4A'><select id='3204B58D4A'><dt id='3204B58D4A'><span id='3204B58D4A'></span></dt></select></label></b><u id='3204B58D4A'></u>
          <i id='3204B58D4A'><strike id='3204B58D4A'><tt id='3204B58D4A'><pre id='3204B58D4A'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:leisure time    Page View:6
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In